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ABSTRACT
Purpose: Prostate cancer growth is dependent upon androgen receptor (AR) 
activation, regulated via phosphorylation. Protein kinase C (PKC) is one kinase that 
can mediate AR phosphorylation. This study aimed to establish if AR phosphorylation 
by PKC is of prognostic significance.
Methods: Immunohistochemistry for AR, AR phosphorylated at Ser-81 (pARS81), 
AR phosphorylated at Ser-578 (pARS578), PKC and phosphorylated PKC (pPKC) was 
performed on 90 hormone-naïve prostate cancer specimens. Protein expression was 
quantified using the weighted histoscore method and examined with regard to clinico-
pathological factors and outcome measures; time to biochemical relapse, survival 
from biochemical relapse and disease-specific survival.
Results: Nuclear PKC expression strongly correlated with nuclear pARS578 (c.c. 
0.469, p=0.001) and cytoplasmic pARS578 (c.c. 0.426 p=0.002). High cytoplasmic and 
nuclear pARS578 were associated with disease-specific survival (p<0.001 and p=0.036 
respectively). High nuclear PKC was associated with lower disease-specific survival 
when combined with high pARS578 in the cytoplasm (p=0.001) and nucleus (p=0.038). 
Combined high total pARS81 and total pARS578 was associated with decreased disease-
specific survival (p=0.005)
Conclusions: pARS578 expression is associated with poor outcome and is a potential 
independent prognostic marker in hormone-naïve prostate cancer. Furthermore, PKC 
driven AR phosphorylation may promote prostate cancer progression and provide a 
novel therapeutic target.
BACKGROUND
Over the last 10 years we have observed increasing 
incidence and decreasing mortality trends in prostate 
cancer. Incidence-mortality ratios were approximately 2:1 
in Western Europe prior to the introduction of PSA testing. 
This ratio has now increased to over 7:1, illustrating the 
level of over-diagnosis [1]. Many patients have indolent 
tumours that, before PSA testing, would not have been 
clinically apparent in their lifetime. Such overdiagnosis 
often results in overtreatment. Treatment of prostate cancer 
with radiation, surgery or hormone therapy is costly and 
even surveillance strategies are expensive. The diagnosis, 
treatment and 5 year follow-up cost of prostate cancer in 
the UK was estimated at £136, 278, 237 in 2010 [2]. It is 
estimated that in 2030 prostate cancer will be the most 
common cancer in men, with rates expected to increase by 
69% compared to the number of new cases in 2007 [3]. If 
the predicted exponential rise in prostate cancer incidence 
and prevalence materialises, the cost of treatment will be 
unsustainable to the UK economy. Therefore the main 
challenge for prostate cancer research and clinical care is 
the quandary of how to continue driving mortality rates 
downward while minimising over-treatment.
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Although the underlying mechanisms driving 
prostate carcinogenesis remain elusive, it is widely 
accepted that prostate cancer cell growth and survival is 
exquisitely dependent upon activation of the androgen 
receptor (AR) by androgens. This explains the high 
response rate of prostate cancer patients to androgen 
deprivation therapy (ADT). ADT reduces the level 
of circulating androgens and therefore levels in the 
prostate cancer cells resulting in AR not being activated, 
causing cell cycle arrest and apoptosis [4]. Furthermore, 
the renewed expression of serum PSA levels and AR 
expression in castrate-resistant disease is evidence that, 
even in advanced disease, prostate cancer cells remain 
almost exclusively dependent on the AR [5, 6]. The AR 
and alterations affecting its functional status are therefore 
likely to play an important role in the development and 
progression of prostate cancer.
Post-translational modification of the AR occurs 
at 23 known sites by phosphorylation, acetylation, 
SUMOylation, methylation and ubiquitination [7, 8]. 
Phosphorylation of the AR at serine residues is thought 
to inhibit proteolytic degradation and stabilize AR 
homo-dimers, thereby enhancing its activity [9]. AR 
phosphorylation may also influence transactivation 
of the AR since AR transcriptional activity correlates 
strongly with phosphorylation of specific serine residues 
[9]. Each of the major AR domains contains at least one 
serine phosphorylation site. The majority of these sites 
are located in the N-terminal domain (NTD), which is 
important for AR transactivation [8]. The hinge region 
contains one serine phosphorylation site, Ser-650, 
which regulates nuclear localization, DNA binding, 
and coactivator recruitment [8, 10, 11]. AR Ser-578 is 
located within the DNA binding domain. Protein kinase 
C (PKC) is the kinase predicted to be responsible for 
phosphorylation of AR Ser-578 [12]. Phosphorylation via 
PKC at this site has been linked to nuclear-cytoplasmic 
shuttling, DNA binding and the modulation of other 
functional phosphorylation sites on the AR [13]. Site 
directed mutagenesis of Ser-578 on the AR in castrate-
resistant prostate cancer cell lines demonstrated that PKC-
dependent phosphorylation was reduced on average by 
50% when compared to wild type cells [13]. In addition 
ligands such as epidermal growth factor (EGF) have been 
shown to increase AR transcriptional activity and cell 
growth via PKC dependent AR phosphorylation at serine 
site 578 [13]. It is therefore plausible that alterations in 
AR phosphorylation, in particular at Ser-578 by PKC, may 
drive prostate carcinogenesis. However, few studies have 
explored the significance of AR phosphorylation at this 
site in prostate cancer in the clinical setting.
In the current study we aim to determine whether 
AR phosphorylation at Ser-578 is associated with 
clinico-pathological parameters and outcome in a 
cohort of hormone-naïve prostate cancer patients and 
if AR phosphorylation at Ser-578 correlates with PKC 
expression. It is hypothesised that AR phosphorylation at 
this site may be associated with disease progression and 
therefore may provide a biomarker to inform treatment 
decision-making.
RESULTS
Patient characteristics
Analysis was based on 90 hormone-naïve prostate 
cancer patients. Patient characteristics recorded include 
age, Gleason score at diagnosis, PSA at diagnosis, 
presence of tissue lymphovascular invasion and PSA at 
recurrence (Table 1). Twenty-three patients had metastases 
to local lymph nodes (3), bone (13) and at both sites (7). 
Forty-seven patients had biochemical relapse (median 
time to biochemical relapse 2.7yr, interquartile range 1.5–
3.8). Twenty-four patients were alive at time of analysis, 
median follow-up 11.7yr (interquartile range 9.9–14.0). 
Forty-six died from prostate cancer (median time to death 
4yr, interquartile range 1.9–7.2) and twenty deaths were 
attributed to inter-current disease (median time to death 
of 4.1yr, interquartile range 0.9–5.5). Table 2  shows 
associations with clinico-pathological parameters and 
clinical outcome measures.
Protein expression analysis
In addition, any tumour exhibiting negative staining 
for pARS578 was demonstrated to have positive staining 
for other AR phosphorylation sites confirming that the 
negative expression was a true negative and not due to 
phospho-proteins being degraded in that particular sample. 
Expression of all proteins was observed at varying levels 
in the cytoplasm and nucleus of both stromal and epithelial 
cells (Figure 1). Protein expression was found to be 
heterogeneous throughout and less intense in the stromal 
cells. There was presence of prostatic intraepithelial 
neoplasia (PIN) and benign tissue, adjacent to the 
neoplastic tissue, in some of the TMA cores. Expression of 
proteins in the interspersed PIN and benign tissue and the 
normal prostate control core was heterogeneous and less 
intense than the neoplastic tissue. Only protein expression 
observed in the tumour cells was recorded. All intra-class 
correlation coefficient (ICCC) values were >0.80. Protein 
expression levels were subdivided into low (≤median) and 
high expression (>median) for analysis (Table 3).
Association between protein expression and 
clinico-pathologic outcome measures
High expression of cytoplasmic pARS578 protein 
was associated with increased Gleason score (p=0.008, 
Table 4). High expression of nuclear pARS578 protein was 
associated with increased PSA level at diagnosis (p=0.015, 
Table 4). High nuclear and cytoplasmic PKC protein 
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expression was associated with increased age (p=0.032 
and p=0.018 respectively, Table 4). High expression of 
nuclear PKC protein was associated with increased PSA 
level at diagnosis (p=0.009, Table 4). Expression of 
pPKC was not significantly associated with any clinico-
pathological outcome measures.
Kinase mediating AR phosphorylation
Scansite 2.0 predicted PKC as a strong candidate 
mediating phosphorylation of AR at Ser-578. In the clinical 
specimens nuclear PKC expression was significantly 
associated with pARS578 expression both in the cytoplasm 
(c.c. 0.426, p=0.002) and nucleus (c.c. 0.469, p=0.001) 
(Table 5, Figure 2). There was no association between 
pPKC expression and pARS578 expression.
Correlation of clinical outcome with pARS578 and 
PKC expression
High nuclear AR was associated with shorter time to 
biochemical relapse (proportion of patients relapsed at 5yr 
78.9% vs 46.7% HR 2.84 (95% CI 1.5–5.3), p=0.001). High 
cytoplasmic pARS578 was also associated with shorter time 
to biochemical relapse (proportion of patients relapsed at 
5 yr 82.1% vs 51.9% HR 2.1 (95% CI 1.0-4.2), p=0.034). 
Interestingly, no association was observed between PKC 
expression and time to biochemical relapse (Table 6).
Survival following disease recurrence was calculated 
from biochemical relapse till death or last follow-up using 
cancer-specific deaths. High expression of cytoplasmic 
pARS578 was associated with less favourable survival 
outcomes following biochemical relapse (10 yr survival 
Table 2: Relationship between clinico-pathological parameters and clinical outcome measures
 Univariate analysis
Clinico-pathological  
characteristic
Time to biochemical relapse
P value, Hazard Ratio  
(95% CI)
Survival from 
biochemical relapse
P value, Hazard Ratio  
(95% CI)
Disease-specific survival
P value, Hazard Ratio  
(95% CI)
Age (<70/>70) 0.260, 1.40, (0.8-2.5) 0.385, 1.44, (0.6-3.3) 0.020, 2.11, (1.1-4.0)
Gleason (<7/7/>7) 0.004, 1.94, (1.3-2.9) 0.060, 1.48, (0.8-2.6) 0.007, 1.91, (1.3-2.9)
PSA at diagnosis (<10/10/>10) 0.002, 1.96, (1.3-2.9) 0.078, 1.46, (0.8-2.7) 0.001, 2.04, (1.3-3.3)
Lymphovascular invasion (no/yes) 0.001, 4.6, (1.7-11.6) 0.612, 1.32, (0.5-3.9) 0.114, 2.09, (0.8-5.3)
PSA at recurrence (<10/10/>10)  <0.001, 5.86, (2.8-12.2) <0.001, 2.82, (1.9-4.2)
Metastases at any time (no/yes) 0.001, 3.65, (1.7-8.0) 0.008, 4.86, (1.4-17.4) <0.001, 5.0, (2.0-12.4)
Ki67 (≤median vs >median) 0.796, 1.08, (0.6-2.0) 0.185, 1.68, (0.8-3.6) 0.006, 2.28, (1.2-4.2)
The clinical variables were grouped and analysed by Kaplan Meier methods with reference to clinical outcome measures 
as shown. Patients were considered to have biochemical relapse dependent on treatment; radical prostatectomy serum 
PSA >0.2ng/ml, radical radiotherapy serum PSA of 2.0ng/ml above the post treatment nadir level, hormone treatment 2-3 
consecutive rises in serum PSA levels above the nadir obtained at intervals of >2 weeks [28, 29]. Numbers in bold denote 
significant associations with p value <0.05.
Table 1: Clinico-pathological characteristics of cohort
 Patients, n (%)
Age (<70/>70) 34 (37.0)/56 (60.9)
Gleason (<7/7/>7) 24 (26.1)/ 25 (27.2)/ 28 (30.4)
PSA at diagnosis (<10/10/>10) 19 (20.7)/ 14 (15.2)/ 36 (39.1)
Lymphovascular invasion (no/yes) 84 (91.3)/ 6 (6.5)
PSA at recurrence (<10/10/>10) 38 (41.3)/ 1 (1.1)/ 10 (10.9)
Ki67 (≤median/>median) 46 (50)/ 39 (42.4)
Number of patients with missing data is not displayed. Values that do not give a sum of 100% is due to data being 
unavailable.
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24.3% vs 58.3% HR 3.2 (95% CI 1.0-9.9), p=0.034). No 
association was observed between PKC, pPKC or AR 
expression and survival from biochemical relapse. (Table 6)
Disease-specific survival was calculated from 
diagnosis till death or last follow-up using cancer-
specific deaths. High nuclear pARS578 was associated with 
decreased disease-specific survival (10 yr survival 30.5% 
vs 63.8% HR 2.24 (95% CI 1.0-4.9), p=0.036) (Table 6, 
Figure 3). High cytoplasmic pARS578 was associated with 
decreased disease-specific survival (10 yr survival 19.7% 
vs 71.3% HR 4.54 (95% CI 2.0-10.4), p<0.001) (Table 6, 
Figure 3). High total pARS578 was associated with decreased 
disease-specific survival (10 yr survival 18.8% (both high) 
vs 75.9% (both low) HR 2.20, (95% CI 1.4-3.5) p=0.002) 
(Table 7). No association was observed between PKC, 
pPKC or AR expression and disease-specific survival.
As nuclear PKC expression correlated strongly 
with pARS578 both in the cytoplasm and the nucleus it was 
investigated as to whether a combination of the two proteins 
could further inform on disease outcome. Nuclear PKC 
expression was therefore combined with cytoplasmic and 
nuclear pARS578 expression as follows: (i) low PKC and low 
pARS578, (ii) high PKC or high pARS578 and (iii) high PKC 
and high pARS578 expression. High PKC and cytoplasmic 
pARS578 expression was associated with disease-specific 
survival (10 yr survival 20.5% vs 46.8% vs 82% HR 2.6 
(95% CI 1.5-4.6), p=0.001) (Figure 4). Similarly high PKC 
and nuclear pARS578 expression was associated with disease-
specific survival (10 yr survival 30.9% vs 44.3% vs 75.6%) 
HR 2.0 (95% CI 1.2-3.4), p=0.038 (Figure 4).
We have previously shown that phosphorylation of 
the androgen receptor at Ser-81 (pARS81) is associated with 
decreased disease-specific survival [14]. The androgen 
receptor is phosphorylated at Ser-81 in response to 
androgens, suggesting these patients would benefit from 
AR targeted therapies. As it is predicted that the AR is 
phosphorylated by PKC at Ser-578, patients with high 
expression of pARS578 may benefit form treatment with a 
PKC inhibitor. We investigated whether assessing pARS81 
in combination with pARS578 would identify a population 
of patients that might benefit from dual targeted therapy 
(AR targeted therapies to inhibit phosphorylation at 
pARS81 and PKC inhibitors to inhibit phosphorylation at 
pARS578). The two phosphorylation sites were combined 
as follows: (i) high pARS81 and high pARS578, (ii) high 
pARS81 or high pARS578 and (iii) low pARS81 and low 
pARS578 expression. High nuclear pARS81 and nuclear 
pARS578 was associated with disease-specific survival (10 
yr survival 20.0% vs 26.3% vs 73.2%, HR 1.85, (95% CI 
1.2-2.9) p=0.011) (Table 7). High cytoplasmic pARS81 and 
cytoplasmic pARS578 was associated with disease-specific 
survival (10 yr survival 15.1% vs 24.4% vs 87.5%, HR 
2.88, (95% CI 1.7-5.0) p=<0.001) (Table 7). Lastly, high 
total pARS81 and total pARS578 was associated with disease-
specific survival (10 yr survival 0% (both high) vs 85.7% 
(both low), HR 1.76, (95% CI 1.3-2.4) p=0.005) (Table 7).
Immunofluorescence
In LNCaP cells DHT and PMA induced AR 
translocation to the nucleus was inhibited by the presence 
of DHT and BIM respectively. DHT induced nuclear 
translocation of AR578 was not clearly evident in LNCaP 
cells suggesting that this is not regulated by DHT, AR578 
nuclear translocation was observed in response to PMA 
and again this was inhibited by BIM, but PMA induced 
Figure 1: Immunohistochemical staining of prostate cancer tissue for AR A., pARS578 B. PKC C. and phosphoPKC D.
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Table 3: Protein expression in patients with tissue available
 Patients, n (%)
AR Nuclear (low/high) 44 (47.8)/ 45 (48.9)
AR Cytoplasmic (low/high) 45 (48.9)/ 44 (47.8)
pARS578 Nuclear (low/high) 30 (32.6)/ 30 (32.6)
pARS578 Cytoplasmic (low/high) 32 (34.8)/ 28 (30.4)
PKC Nuclear (low/high) 30 (32.6)/ 28 (30.4)
PKC Cytoplasmic (low/high) 29 (31.5)/ 29 (31.5)
pPKC Nuclear (low/high) 41 (44.6)/ 40 (43.5)
pPKC Cytoplasmic (low/high) 41 (44.6)/ 40 (43.5)
The proteins of interest were grouped as ≤median or >median. Number of patients with missing data is not displayed. 
Values that do not give a sum of 100% is due to data being unavailable.
Table 4: Clinico-pathological factors related to pAR578 and PKC expression
 
 
Nuclear pAR578 Cytoplasmic pAR578 Nuclear PKC Cytoplasmic PKC
Low 
expression
High 
expression
p-value Low 
expression
High 
expression
p-value Low 
Expression
High 
expression
p-value Low 
expression
High 
expression
p-value
Age (<70/>70) 14/16 10/20 0.296 16/16 8/20 0.94 17/13 8/20 0.032 17/12 8/21 0.018
Gleason (<7/7/>7) 9/10/7 8/7/12 0.324 13/9/6 4/8/13 0.008 10/10/7 10/3/12 0.431 10/7/8 10/6/11 0.630
PSA at diagnosis 
(<10/10/>10) 9/4/11 2/5/19 0.015 8/5/13 3/4/17 0.096 9/8/9 3/3/18 0.009 7/7/13 5/4/14 0.478
Lymphovascular 
invasion (no/yes) 27/3 27/3 1.000 30/2 24/4 0.305 27/3 26/2 0.701 26/3 27/2 0.643
PSA at recurrence 
(<10/10/>10) 13/0/3 13/0/6 0.394 15/0/2 11/0/7 0.071 12/0/6 11/0/4 0.683 12/0/5 11/0/5 0.910
Metastases at any 
time (no/yes) 11/6 8/10 0.236 12/9 7/7 0.682 9/7 11/6 0.625 13/5 7/8 0.141
Ki67 
(≤median/>median)
17/10 18/10 0.920 16/12 19/8 0.312 17/9 16/12 0.539 17/9 16/12 0.539
Expression of pARS578 in the nucleus and cytoplasm was examined for significant relationships with clinical variables as 
shown. Protein expression was divided into high and low groups. Clinical variables were divided into groups and used for 
statistical analysis. When the clinical variable consisted of 2 independent groups the Mann-Whitney U test was performed, 
and >2 independent groups the Kruskal-Wallis test was used. Significant associations are highlighted in bold.
Table 5: Associations between protein expression of pARS578 and kinase expression (PKC and pPKC)
 PKC pPKC
 Nuclear
P value, C.C
Cytoplasmic
P value, C.C
Nuclear
P value, C.C
Cytoplasmic
P value, C.C
pAR578 Nuclear 0.001, 0.469 0.044, 0.284 0.253, 0.155 0.256, 0.154
pAR578 Cytoplasmic 0.002, 0.426 0.894, 0.019 0.790, 0.036 0.649, 0.062
C.C. denotes Pearson’s correlation co-efficient
Values in bold denotes associations with Pearson’s correlation co-efficient > 0.4 and p value < 0.05.
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AR578 nuclear translocation was to a lesser extend than 
that observed with AR (Figure 5).
DISCUSSION
The current study demonstrates that phosphorylation 
of AR at Ser-578 is strongly associated with PKC expression. 
In addition, the expression of pARS578 in hormone-naïve 
prostate cancer was observed to be a negative prognostic 
marker associated with shorter time to biochemical relapse, 
decreased survival from biochemical relapse and decreased 
disease-specific survival. Although we were unable to 
demonstrate any significant association between pPKC 
expression and clinico-pathological outcome measures, there 
was a trend towards significance between high expression of 
both nuclear and cytoplasmic pPKC and increased Gleason 
score (p=0.09 and p=0.103 respectively).
In agreement with previous reports PKC expression 
correlated strongly with pARS578 expression [13]. Previous 
site directed mutagenesis work in castrate-resistant cell 
lines has demonstrated that PKC induced phosphorylation 
is reduced in pARS578 knock down cells [13]. The current 
study adds to this by suggesting that the link between PKC 
and AR phosphorylation is also present in hormone naïve 
prostate cancer tissue and therefore may have important 
implications in both early and late stages of the disease. 
Similar site directed mutagenesis studies are necessary 
in prostate cancer cell lines established from localised 
disease in order to confirm this finding.
We observed significant associations between 
protein expression and outcome measures for both 
nuclear and cytoplasmic pARS578. Indeed, the presence 
of cytoplasmic AR is expected as the AR localizes to 
the cytoplasm in the absence of ligand-binding due to a 
ligand-regulated nuclear export signal [15, 16]. Previous 
mutagenesis studies investigated the effect on subcellular 
localization of AR in COS cells. This work demonstrated 
that in wild type pARS578 cells AR is distributed between 
the nucleus and cytoplasm indicative of nuclear-
cytoplasmic shuttling [13]. However in cells where 
the pARS578 site was mutated AR expression was found 
exclusively in the nucleus [13]. The current study is in 
agreement with this work and provides further evidence 
for the involvement of pARS578 in nuclear-cytoplasmic 
shuttling in neoplastic prostate tissue.
Protein kinase C is the kinase predicted to be 
responsible for phosphorylation at Ser-578 on the AR. We 
have found that whilst pARS578 predicts disease-specific 
survival, PKC expression alone does not. When expression 
of pARS578 was combined with PKC expression however, 
the two proteins together were still able to inform on 
disease-specific survival. No additive effect was observed 
in terms of significance when pARS578 was combined with 
PKC to predict disease-specific survival, suggesting that 
PKC and pARS578 are involved in the same pathway.
It is well established that Ser-81 is phosphorylated 
in response to androgen binding on the androgen receptor 
[8, 17]. We investigated whether there was a cumulative 
predictive effect in terms of disease-specific survival 
when two AR phosphorylation sites with two independent 
pathways were combined. Predictive power was increased 
when pARS81 and pARS578 expression was combined 
than compared to using pARS81 or pARS578 expression 
independently. These results are of great importance 
clinically, as it highlights a sub-population of patients who 
may benefit from dual targeted therapy with androgen 
deprivation therapy and PKC inhibitors. Unfortunately, 
Figure 2: Scatter plots illustrating the correlation of PKC nuclear expression with pARS578 nuclear A. and cytoplasmic 
B. expression. Line represents best fit line with mean 95% confidence intervals. Pearson’s correlation coefficient (c.c.) >0.4 and p<0.05 
is considered significant.
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to date, oncology clinical trials have had little success in 
utilising PKC inhibitors either due to poor efficacy, or 
significant intolerable side effects [18]. This study adds to 
the existing body of evidence that PKC has a role in prostate 
cancer, and as such encourages further work in drug 
development of an efficacious PKC inhibitor. Future work 
would consist of investigating expression of pARS81 and 
pARS578 in prostate cancer cell lines in response to treatment 
with androgen deprivation therapy and PKC inhibitors.
The prognostic significance of AR serine 
phosphorylation has been investigated previously 
by ourselves and others [14, 19, 20]. However, to 
our knowledge, this is the first in vivo report of the 
prognostic significance of AR phosphorylation at serine 
site 578. Previous work relating to total AR expression 
has demonstrated widely conflicting results. In support 
of its use as a negative prognostic marker in prostate 
cancer an investigation of 115 hormone naïve radical 
prostatectomy specimens demonstrated that higher 
tumour AR gene expression was associated with shorter 
time to biochemical recurrence [21]. Three further studies 
with a total of 788 patients demonstrated that higher 
Table 6: Univariate analysis of AR, pARS578, PKC and pPKC expression and clinical outcome measures
 
 
Univariate analysis
Time to biochemical relapse
P value Hazard Ratio  
(95% CI)
Survival from biochemical relapse
P value Hazard Ratio  
(95% CI)
Disease-specific survival
P value Hazard Ratio  
(95% CI)
AR Nuclear 0.001, 2.84, (1.5-5.3) 0.688, 1.18, (0.5-2.7) 0.233, 1.44, (0.8-2.6)
AR Cytoplasmic 0.466, 1.23, (0.7-2.2) 0.922, 0.96, (0.4-2.1) 0.517, 1.21, (0.7-2.2)
pARS578 Nuclear 0.461, 1.30, (0.6-2.6) 0.347, 1.62, (0.6-4.5) 0.036, 2.24, (1.0-4.9)
pARS578 Cytoplasmic 0.034, 2.1, (1.0-4.2) 0.034, 3.19, (1.0-9.9) <0.001, 4.54, (2.0-10.4)
PKC Nuclear 0.712, 0.88, (0.4-1.8) 0.450, 1.46, (0.5-3.9) 0.203, 1.68, (0.8-3.7)
PKC Cytoplasmic 0.938, 1.03, (0.5-2.1) 0.799, 1.14, (0.4-3.1) 0.269, 1.56, (0.7-3.5)
pPKC Nuclear 0.764, 1.10, (0.6-2.0) 0.403, 1.42, (0.6-3.2) 0.890, 1.05, (0.6-2.0)
pPKC Cytoplasmic 0.877, 0.96, (0.5-1.7) 0.647, 0.82, (0.4-1.9) 0.946, 0.98, (0.5-1.9)
Univariate analysis of AR and pAR protein expression was carried out using Kaplan Meier methods with reference to 
the clinical outcome measures. Patients were considered to have biochemical relapse dependent on treatment; radical 
prostatectomy serum PSA >0.2ng/ml, radical radiotherapy serum PSA of 2.0ng/ml above the post treatment nadir level, 
hormone treatment 2-3 consecutive rises in serum PSA levels above the nadir obtained at intervals of >2 weeks [28, 29]. 
Numbers in bold denote significant associations with p value <0.05.
Figure 3: Kaplan-Meier survival plots illustrating disease-specific survival in patients with high (dashed line) and low 
(solid line) nuclear A. and cytoplasmic B. pARS578 expression.
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AR expression was associated with a worse prognosis 
[22–24]. In support of this, AR gene amplification and 
corresponding increase in expression at the protein level 
has been shown in castrate-resistant tumour samples when 
compared to matched hormone sensitive samples from the 
same patient [25]. Similarly, hormone sensitive prostate 
cancer xenografts in castrated mice demonstrated an 
increase in AR gene and protein expression in addition 
to the acquisition of the ability of the AR to respond to 
anti-androgens and to aberrantly recruit coactivators to 
the promoters [26]. However, other work, including a 
large study involving a tissue microarray of 2805 prostate 
cancers, has shown no association of AR expression with 
prognosis [27]. These conflicting findings may depend 
on several factors such as tissue heterogeneity, timing of 
specimen dissection, and methods to detect AR expression 
including the use of different antibodies. In addition, the 
simple expression of AR does not reflect its function or 
its activity, and therefore may account for the variations 
reported with regards to prognostic significance. AR 
phosphorylation, which is known to provide molecular 
stability, may therefore be a marker of activation. This 
current study lends support to this argument as we have 
demonstrated that those patients who have a high level of 
pARS578 have reduced overall survival when compared to 
AR expression alone.
We acknowledge the possibility of cross-reactivity 
in the usage of a phospho-specific antibody particularly on 
a protein such as AR with multiple phosphorylation sites. 
However the specificity of phospho-AR antibodies has 
been stringently tested by our group previously and they 
have been found to be of suitable quality (Figure 6) [14]. 
Table 7: Univariate analysis of combined phosphorylated AR sites and disease-specific survival
Univariate analysis
 Disease-specific survival
P value Hazard Ratio (95% CI)
Total pARS578 0.002, 2.20, (1.4-3.5)
Total pARS81 0.034, 1.78, (1.1-2.7)
pARS578 cytoplasmic + pARS81 cytoplasmic <0.001, 2.88, (1.7-5.0)
pARS578 nuclear + pARS81 nuclear 0.011, 1.85, (1.2-2.9)
Total pARS578 + Total pARS81 0.005, 1.76, (1.3-2.4)
Univariate analysis of total and combine pAR protein expression was carried out using Kaplan Meier methods with 
reference to disease-specific survival.
Figure 4: Kaplan-Meier survival plots illustrating disease-specific survival in hormone-naïve prostate cancer patients 
with nuclear PKC expression combined with nuclear A. and cytoplasmic B. pARS578 expression. Protein expression was 
divided for analysis as low (≤median) and high (>median) and nuclear PKC expression was combined with pARS578 expression to give the 
following scores; low nuclear PKC and pARS578 (solid line), high nuclear PKC or pARS578 (dotted line) and high nuclear PKC and pARS578 
(dashed line).
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Figure 5: Immunofluorescent image demonstrating that nuclear translocation of AR in response to DHT or PMA can 
be inhibited by enzalutamide and BIM and nuclear translocation of AR578 in response to PMA can be inhibited by 
BIM.
Figure 6: Blocking peptide experiments for pARS578 are shown. The top row represents the positive control i.e. IHC conducted 
with each AR phosphospecific antibody as indicated. The bottom row represents antibodies to AR phosphorylation sites pre-incubated 
with pARS578 peptide. The specific peptide utilised is boxed in red. No staining is demonstrated when the pARS578 peptide is incubated with 
pARS578antibody, whereas staining is maintained at the other phospho-AR sites.
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To follow on from both the previous and the current study 
we intend to validate these findings in a larger independent 
patient cohort.
An obvious limitation of this study is the small 
sample size and as such the results should be interpreted 
with caution and validated in a large independent cohort. 
However, even with low patient numbers, we have 
demonstrated that AR phosphorylation by PKC at serine 
578 is of prognostic significance. These results are striking 
in particular when considered that this was a hormone-
naïve cohort of patients who subsequently received a 
variety of treatments (surgery, radiotherapy and hormones) 
and that, due to small numbers, we were unable to unpick 
these groups. We were unable to show any significant 
associations between pPKC and pARS578 expression, nor 
with any clinical outcome measures. Again, this may be 
due to the small sample size. We now intend to repeat this 
work in two further cohorts: firstly a cohort of prostate 
cancer patients treated with active surveillance, and 
secondly a larger cohort of hormone-naïve prostate cancer 
patients.
conclusions
This study provides further evidence for the 
significance of androgen receptor signalling in the 
progression of prostate cancer. We have demonstrated 
that PKC may phosphorylate AR at serine 578 and that, 
in combination with current diagnostic tools, pARS578 
protein expression could provide a desperately needed 
prognostic marker to aid treatment decision-making 
in prostate cancer patients at diagnosis. Furthermore, 
PKC-driven AR phosphorylation may be a potential 
novel therapeutic target. This finding has the potential to 
reduce over-treatment of clinically insignificant disease 
and prevent delay in treatment of occult aggressive 
disease.
MATERIALS AND METHODS
Patients
Ninety patients with hormone-naïve prostate 
cancer samples available were recruited at the Glasgow 
Royal Infirmary between 1992 and 2002. Last date 
of follow up was 11/01/2012. Patients gave written 
consent. Clinical data included age, Gleason score, 
tumour lymphovascular invasion (LVI), serum PSA 
levels at diagnosis, biochemical recurrence, serum PSA 
at biochemical recurrence and presence of metastases. 
Patients were considered to have biochemical recurrence 
dependent on treatment; radical prostatectomy serum PSA 
>0.2ng/ml, radical radiotherapy serum PSA of 2.0ng/ml 
above the post treatment nadir level, hormone treatment 
2-3 consecutive rises in serum PSA levels above the 
nadir obtained at intervals of >2 weeks [28, 29]. Study 
end points were biochemical relapse, survival from 
biochemical relapse and disease-specific survival. West of 
Scotland Research Ethics Committee approved the study 
(reference: 05/S0704/94).
Identification of Kinases mediating AR 
phosphorylation
Scansite 2.0 was utilised to predict which sites on 
the AR would be phosphorylated by PKC [12]. The search 
was conducted using the protein ID “ANDR_HUMAN” 
(Accession number: P10275).
Tissue microarray (TMA) construction
Three 0.6mm2 cores of prostate cancer tissue, 
identified by a uropathologist, were removed from 
formalin-fixed paraffin-embedded blocks. Recipient 
array blocks were constructed in triplicate. Control 
cores of normal prostate, colon, breast, pancreas, tonsil, 
kidney, liver and lung tissue were included in each 
TMA.
Immunohistochemistry (IHC)
AR expression, pARS81 expression and 
proliferation index (Ki67) was already available for 
this cohort [14]. IHC was conducted in triplicate on 
aforementioned TMAs for the following proteins 
pARS578, PKC, and pPKC. Antibody to pARS578 was 
not commercially available and so was synthesized 
for this project by Covalab, Villeurbanne, France. In 
brief, host animals were immunized with conjugated 
phosphorylated peptide for the protein sequence 
HYGALTCG[Sp]CKVF. Animals were serially bled and 
following the final bleed phospho-specific antibodies 
were selected by affinity purification. Two affinity 
columns were used; the first column coupled with the 
non-phosphorylated peptide and the second column 
with the phosphorylated peptide. The serum was passed 
through the first column and the non-retaining elute 
kept and used for the second purification. The elute 
was purified on the second column in order to remove 
antibodies which might recognise the un-phosphorylated 
peptide. ELISA tests were performed to ensure that the 
recovered antibody was specific for phosphorylation of 
AR specifically at Ser-578.
TMAs were dewaxed in xylene and rehydrated 
through graded alcohol. Antigen retrieval for PKC and 
pPKC was performed using heat treatment under pressure 
in citrate buffer pH6, 5min. Antigen retrieval for pARS578 
was performed using heat treatment under pressure in 
Tris-EDTA buffer (5mM Trizma Base, 1mM EDTA, 
pH8), 5min. Sections were cooled in buffer for 20min 
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before washing in 3% H202. Sections were blocked using 
5% horse serum in Tris-buffered saline (TBS). Antibodies 
for PKC (#ab59363, Abcam, UK), pPKC (SC -11760, 
Santa Cruz, USA) and pARS578 (Covalab, France) were 
incubated overnight at 4°C diluted at 1:100, 1:120 and 
1:500 respectively. All antibodies were diluted in Dako 
antibody diluent (Dako UK Ltd.). Bound antibody 
complex was visualized using EnVision plus kit (#K5007, 
Dako UK Ltd.) followed by 3,3-diaminobenzidine 
tetrahydrochloride (DAB, Dako UK Ltd.). Nuclei were 
counterstained with haematoxylin and Scots Tap Water 
Substitute. Finally, sections were dehydrated through 
graded alcohol and xylene and mounted with Di-N-
ButylePhthalate in Xylene.
Antibody validation
Peptide competition assays were performed to 
confirm pARS578 antibody specificity. pARS578 peptide 
(Protein sequence ALTCG-S(pS)-CKVFFKR raised 
in rabbit by Eurogentec Ltd., Seraing, Belgium) was 
incubated at ratio 200:1 with pARS81, pARS94, pARS308, 
pARS515, pARS578 and pARS650 antibodies overnight at 4°C. 
IHC was then performed as described above. Peptide 
competition assay demonstrated that only staining in 
response to antibody raised to pARS578 was blocked and 
staining to other phosphorylation sites was not altered 
(Figure 6).
Scoring
Tissue staining intensity was scored by two blinded 
independent observers using a weighted histo-score 
(H-score) method [30, 31]. H-score was calculated from 
the formula: (0 x % cells staining negative) + (1 x % 
cells staining weakly positive) + (2 x % cells staining 
moderately positive) + (3 x % cells staining strongly 
positive). The mean H-score from staining conducted 
in triplicate was used for analysis. Signals for nuclear 
and cytoplasmic pAR immunoreactivity were evaluated 
separately.
Statistical analysis
Statistical analysis was performed using SPSS 
version 19.0 for Windows (IBM). ICCCs confirmed 
histo-scoring consistency between observers. Pearson’s 
rank correlation coefficients (c.c.) assessed associations 
between protein expression. Mann-Whitney U test or 
Kruskal-Wallis test assessed relationships between 
protein expression and clinico-pathologic characteristics. 
Kaplan-Meier methods, using the log-rank test, compared 
survival between patients according to clinico-pathologic 
parameters and high/low protein expression. A <0.05 
significance level was used and Bonferroni correction was 
applied where applicable.
Immunofluorescence
LNCaP cells were seeded at 2.5 x 104 cells per well 
in a 6 well chamber slide. Cells were cultured in RPMI 
supplemented with Glutamax, penicillin streptomycin 
and fetal bovine serum at 37°C in 5% CO2 until cells had 
reached 70% confluency. Cells were cultured in serum-
free media for 24 hours. The LNCaP cells were treated 
with 1 nM dihydrotestosterone (DHT) or 1 nM phorbol 
12-myristate 13-acetate (PMA), a PKC activator, or 1 
nM DHT and 10 nM enzalutamide (antiandrogen) or 1n 
M PMA and 10 nM Bisindolymaleimide 1 (BIM-1), a 
PKC inhibitor, for one hour. Cells were fixed with 4% 
PFA at 4°C for 30 minutes. Cells were washed twice 
with PBS for five minutes on a rocker. Cells were 
permeabilised by treating twice with 0.1% Triton X-100 
for five minutes. Blocking solution (1.5% horse serum 
in 0.1% TBS-tween) was applied for thirty minutes on 
a rocker at room temperature. Primary antibody, diluted 
in blocking solution (AR, 1:200 (DAKO), pARS578, 
1:100 (Covalab)) was applied for one hour at room 
temperature. Cells were washed three times in TBS for 
ten minutes. Secondary antibody, diluted in blocking 
buffer, (Goat anti-mouse IgG secondary Alexa-Fluor 
488, 1:500 (ThermoFisher) and Goat anti-rabbit IgG 
secondary Alexa-Fluor 488, 1:500 (ThermoFisher) was 
applied to the cells treated with the respective primary 
antibodies for one hour in the dark at room temperature. 
Cells were washed three times in TBS for five minutes. 
Vectashield mounting medium with DAPI (Vectorlabs) 
was used to counterstain DNA in the nucleus. The 
cells were visualised using confocal microscopy. Each 
experiment was performed in triplicate and repeated 3 
times.
ACKNOWLEDGMENTS
This study was supported by funding from the 
Association of International Cancer Research, Think 
Pink and NHS Greater Glasgow and Clyde Research 
Endowment Fund.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest.
REFERENCES
1. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay 
J, Brawley O, Bray F. International variation in prostate 
cancer incidence and mortality rates. European urology. 
2012; 61:1079-1092.
Oncotarget4886www.impactjournals.com/oncotarget
2. Roehrborn CG, Black LK. The economic burden of prostate 
cancer. BJU international. 2011; 108:806-813.
3. Mistry M, Parkin DM, Ahmad AS, Sasieni P. 
Cancer incidence in the United Kingdom: projections 
to the year 2030. British journal of cancer. 2011; 
105:1795-1803.
4. Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, 
Golde DW, Scher HI. Prostate cancer cell cycle regulators: 
response to androgen withdrawal and development of 
androgen independence. Journal of the National Cancer 
Institute. 1999; 91:1869-1876.
5. Chen Y, Sawyers CL, Scher HI. Targeting the androgen 
receptor pathway in prostate cancer. Current opinion in 
pharmacology. 2008; 8:440-448.
6. Fleming MT, Morris MJ, Heller G, Scher HI. Post-therapy 
changes in PSA as an outcome measure in prostate cancer 
clinical trials. Nature clinical practice Oncology. 2006; 
3:658-667.
7. Kuiper GG, Brinkmann AO. Phosphotryptic peptide 
analysis of the human androgen receptor: detection of a 
hormone-induced phosphopeptide. Biochemistry. 1995; 
34:1851-1857.
8. Gioeli D, Paschal BM. Post-translational modification of the 
androgen receptor. Molecular and cellular endocrinology. 
2012; 352:70-78.
9. Blok LJ, de Ruiter PE, Brinkmann AO. Forskolin-induced 
dephosphorylation of the androgen receptor impairs ligand 
binding. Biochemistry. 1998; 37:3850-3857.
10. Gioeli D, Black BE, Gordon V, Spencer A, Kesler CT, 
Eblen ST, Paschal BM, Weber MJ. Stress kinase signaling 
regulates androgen receptor phosphorylation, transcription, 
and localization. Molecular endocrinology. 2006; 
20:503-515.
11. Zhou ZX, Kemppainen JA, Wilson EM. Identification of 
three proline-directed phosphorylation sites in the human 
androgen receptor. Molecular endocrinology (Baltimore, 
Md). 1995; 9:605-615.
12. Obenauer JC, Cantley LC, Yaffe MB. Scansite 2.0: 
Proteome-wide prediction of cell signaling interactions 
using short sequence motifs. Nucleic acids research. 2003; 
31:3635-3641.
13. Ponguta LA, Gregory CW, French FS, Wilson EM. Site-
specific androgen receptor serine phosphorylation linked to 
epidermal growth factor-dependent growth of castration-
recurrent prostate cancer. The Journal of biological 
chemistry. 2008; 283:20989-21001.
14. Willder JM, Heng SJ, McCall P, Adams CE, Tannahill C, 
Fyffe G, Seywright M, Horgan PG, Leung HY, Underwood 
MA, Edwards J. Androgen receptor phosphorylation 
at serine 515 by Cdk1 predicts biochemical relapse in 
prostate cancer patients. British journal of cancer. 2013; 
108:139-148.
15. Tyagi RK, Lavrovsky Y, Ahn SC, Song CS, Chatterjee 
B, Roy AK. Dynamics of intracellular movement and 
nucleocytoplasmic recycling of the ligand-activated 
androgen receptor in living cells. Molecular endocrinology. 
2000; 14:1162-1174.
16. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz 
G, Yan DH, Hung MC. HER-2/neu promotes androgen-
independent survival and growth of prostate cancer 
cells through the Akt pathway. Cancer research. 2000; 
60:6841-6845.
17. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock 
M, Catling AD, White FM, Christian RE, Settlage RE, 
Shabanowitz J, Hunt DF, Weber MJ. Androgen receptor 
phosphorylation. Regulation and identification of the 
phosphorylation sites. The Journal of biological chemistry. 
2002; 277:29304-29314.
18. Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an 
elusive therapeutic target? Nature reviews Drug discovery. 
2012; 11:937-957.
19. Ha S, Iqbal NJ, Mita P, Ruoff R, Gerald WL, Lepor H, 
Taneja SS, Lee P, Melamed J, Garabedian MJ, Logan 
SK. Phosphorylation of the androgen receptor by PIM1 
in hormone refractory prostate cancer. Oncogene. 2013; 
32:3992-4000.
20. McCall P, Gemmell LK, Mukherjee R, Bartlett JM, 
Edwards J. Phosphorylation of the androgen receptor is 
associated with reduced survival in hormone-refractory 
prostate cancer patients. British journal of cancer. 2008; 
98:1094-1101.
21. Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao 
C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, 
Petrovics G. Higher tumor to benign ratio of the androgen 
receptor mRNA expression associates with prostate cancer 
progression after radical prostatectomy. Urology. 2007; 
70:1225-1229.
22. Inoue T, Segawa T, Shiraishi T, Yoshida T, Toda Y, Yamada 
T, Kinukawa N, Kinoshita H, Kamoto T, Ogawa O. 
Androgen receptor, Ki67, and p53 expression in radical 
prostatectomy specimens predict treatment failure in 
Japanese population. Urology. 2005; 66:332-337.
23. Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala 
G. High level of androgen receptor is associated with 
aggressive clinicopathologic features and decreased 
biochemical recurrence-free survival in prostate: cancer 
patients treated with radical prostatectomy. The American 
journal of surgical pathology. 2004; 28:928-934.
24. Henshall SM, Quinn DI, Lee CS, Head DR, Golovsky 
D, Brenner PC, Delprado W, Stricker PD, Grygiel JJ, 
Sutherland RL. Altered expression of androgen receptor in 
the malignant epithelium and adjacent stroma is associated 
with early relapse in prostate cancer. Cancer research. 2001; 
61:423-427.
Oncotarget4887www.impactjournals.com/oncotarget
25. Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen 
receptor gene amplification and protein expression in 
hormone refractory prostate cancer. British journal of 
cancer. 2003; 89:552-556.
26. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella 
R, Rosenfeld MG, Sawyers CL. Molecular determinants of 
resistance to antiandrogen therapy. Nature medicine. 2004; 
10:33-39.
27. Minner S, Enodien M, Sirma H, Luebke AM, Krohn 
A, Mayer PS, Simon R, Tennstedt P, Muller J, Scholz L, 
Brase JC, Liu AY, Schluter H, Pantel K, Schumacher 
U, Bokemeyer C, et al. ERG status is unrelated to PSA 
recurrence in radically operated prostate cancer in the 
absence of antihormonal therapy. Clinical cancer research. 
2011; 17:5878-5888.
28. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, 
D'Amico AV, Dmochowski RR, Eton DT, Forman JD, 
Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul 
JW, Tangen C, Thrasher JB, Thompson I. Variation in the 
definition of biochemical recurrence in patients treated 
for localized prostate cancer: the American Urological 
Association Prostate Guidelines for Localized Prostate 
Cancer Update Panel report and recommendations for a 
standard in the reporting of surgical outcomes. The Journal 
of urology. 2007; 177:540-545.
29. Roach M, 3rd, Hanks G, Thames H, Jr., Schellhammer P, 
Shipley WU, Sokol GH, Sandler H. Defining biochemical 
failure following radiotherapy with or without hormonal 
therapy in men with clinically localized prostate cancer: 
recommendations of the RTOG-ASTRO Phoenix 
Consensus Conference. International journal of radiation 
oncology, biology, physics. 2006; 65:965-974.
30. Kirkegaard T, Edwards J, Tovey S, McGlynn LM, Krishna 
SN, Mukherjee R, Tam L, Munro AF, Dunne B, Bartlett 
JM. Observer variation in immunohistochemical analysis 
of protein expression, time for a change? Histopathology. 
2006; 48:787-794.
31. McCarty KS, Jr., Szabo E, Flowers JL, Cox EB, Leight 
GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman 
WT and et al. Use of a monoclonal anti-estrogen receptor 
antibody in the immunohistochemical evaluation of human 
tumors. Cancer research. 1986; 46:4244s-4248s.
